Diatos doxorubicin prodrug well-tolerated at Ph I

Paris, France-based cancer specialist Diatos SA reported positive data from a Phase I trial of its drug, DTS-201, at the 43rd annual meeting of the American Society of Clinical Oncology, in Chicago. The agent, which is a doxorubicin prodrug being developed for the targeted treatment of several solid cancers, was shown to be well tolerated and able to deliver high doses of free doxorubicin in humans.

In the Phase I evaluation, DTS-201 was well-tolerated by 25 cancer patients treated with doses of up to 400mg/m2 every three weeks, which corresponds to 3.75 times the standard dose of the active substance. The agent was also safe and well tolerated at cumulative doses of up to 2,750mg/m2, evidence of clinical efficacy was observed: two patients showed partial responses and three patients with chemo-resistant tumors showed disease stabilization.